Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
Director Diana Hausman of Immuneering Corp (NASDAQ: IMRX) recently purchased shares of the company’s Class A Common Stock. On July 2, 2025, Hausman engaged in two purchase transactions, acquiring a total of 5,500 shares for approximately $19,862. The insider purchase comes as the company’s stock has shown remarkable strength, delivering a 216% return over the past year. According to InvestingPro data, the company maintains a strong financial position with a current ratio of 7.48 and more cash than debt on its balance sheet.
The prices paid for these shares ranged from $3.5956 to $3.6245. Hausman directly purchased 2,500 shares and indirectly purchased 3,000 shares through a spouse. With analyst price targets ranging from $3.50 to $21, and 11 additional InvestingPro tips available, investors seeking deeper insights into IMRX’s potential can access comprehensive analysis through the platform.
In other recent news, Immuneering Corporation announced positive interim data from its Phase 2a clinical trial evaluating the drug atebimetinib in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer patients. The trial showed a 94% overall survival rate and a 72% progression-free survival rate at six months, surpassing standard care benchmarks. The company observed a 39% overall response rate and an 81% disease control rate, with several patients experiencing significant tumor regression. Mizuho (NYSE:MFG) raised its price target for Immuneering to $10 from $8, maintaining an Outperform rating due to the drug’s favorable safety profile and potential as a best-in-class treatment. Immuneering plans to increase trial enrollment to approximately 50 patients and aims to initiate a pivotal trial in 2026. Additionally, the company held its Annual Meeting of Stockholders, electing three Class I directors and ratifying RSM US LLP as its independent registered public accounting firm. These developments reflect Immuneering’s ongoing efforts to advance its pancreatic cancer treatment and strengthen its corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.